麦科医药-B(02335)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02335 麦科医药-B

休市中 10-23 16:08:08

14.420

-0.980

-6.36%

最高15.500	最低13.130	成交量444.07万
今开15.500	昨收15.400	日振幅15.39%
总市值47.84亿	流通市值40.39亿	总股本3.32亿
成交额6,302万	换手率1.59%	流通股本2.80亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02335","market":"HK","secType":"STK","nameCN":"麦科医药-B","latestPrice":14.42,"timestamp":1792742888121,"preClose":15.4,"halted":0,"volume":4440680,"delay":0,"changeRate":-0.06363636363636366,"floatShares":280071100,"shares":331740350,"eps":0,"marketStatus":"休市中","change":-0.98,"latestTime":"10-23 16:08:08","open":15.5,"high":15.5,"low":13.13,"amount":63024334,"amplitude":0.153896,"askPrice":14.43,"askSize":1400,"bidPrice":14.42,"bidSize":1400,"shortable":0,"etf":0,"ttmEps":-1.265,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792978200000},"marketStatusCode":7,"adr":0,"listingDate":1782230400000,"exchange":"SEHK","adjPreClose":15.4,"openAndCloseTimeList":[[1792719000000,1792728000000],[1792731600000,1792742400000]],"volumeRatio":0.5765469606086573,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02335/tweets","defaultTab":"tweets","newsList":[{"id":"1187932080","title":"麦科医药-B（02335）拟11月10日召开临时股东会　审议10% H股回购授权","url":"https://stock-news.laohu8.com/highlight/detail?id=1187932080","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187932080?lang=zh_cn&edition=full","pubTime":"2026-10-22 22:36","pubTimestamp":1792679762,"startTime":"0","endTime":"0","summary":"特别决议案——向董事会授予一般授权，在“相关期间”内回购不超过已发行且未被回购H股总数10%的股份。“相关期间”自该决议获通过之日起，至下一届年度股东大会结束或股东另行撤销、修订该授权之日止。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164121317","title":"麦科医药-B拟回购最多10%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1164121317","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164121317?lang=zh_cn&edition=full","pubTime":"2026-10-22 22:35","pubTimestamp":1792679746,"startTime":"0","endTime":"0","summary":"麦科医药-B于2026年10月22日发布公告，董事会提议授予其回购H股的一般性授权，规模最高可达公司已发行H股总数的10%。公告显示，截至最后实际可行日期，麦科医药-B已发行H股数量为280,071,100股，此次授予的回购上限约为28,007,110股。为厘定有权出席该临时股东大会并投票的股东名单，公司将于2026年11月5日至11月10日暂停办理H股股份过户手续。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"麦科医药-B拟回购最多10%股份","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676265485","title":"港股异动 | 麦科医药-B(02335)回落逾20% 公司宣布股权激励及回购计划 现有资金支持足以研发投入","url":"https://stock-news.laohu8.com/highlight/detail?id=2676265485","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676265485?lang=zh_cn&edition=full","pubTime":"2026-10-20 13:44","pubTimestamp":1792475062,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，麦科医药-B上一交易日放量飙升166%，当日收涨64%，今日股价回落逾20%。消息面上，麦科医药拟提请股东大会批准10年的H股股权激励计划，以绑定核心研发团队，并提请股东大会授予回购不超过已发行H股总数10%股份的一般授权。董事会认为，H股当前市价未能充分反映公司基本面及长期增长潜力，现有资金足以支持公司未来长期的研发投入。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1509283.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","APLY","AAPE","AAPD","BK1161","BK4588","02335","IOSX","AAPU","AAPW","KCAI","AAPY","AAPB","AAPX","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675503355","title":"港股异动 | 麦科医药-B(02335.HK)飙升逾115% 采纳H股激励计划并寻求回购不超过10%H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2675503355","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675503355?lang=zh_cn&edition=full","pubTime":"2026-10-16 11:19","pubTimestamp":1792120742,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02335","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129313278","title":"麦科医药-B（02335.HK）拟设立十年期H股激励计划并申请10%回购授权","url":"https://stock-news.laohu8.com/highlight/detail?id=1129313278","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129313278?lang=zh_cn&edition=full","pubTime":"2026-10-15 20:35","pubTimestamp":1792067741,"startTime":"0","endTime":"0","summary":"10月15日，麦科医药-B公告称，公司董事会于2026年10月15日交易时段后审议通过两项议案，将在即将召开的临时股东大会上提交表决：一是建议采纳为期十年的H股激励计划；二是建议授予不超过已发行H股总数10%的股份回购一般授权。回购的H股可根据市场情况及资本管理需要，选择注销或转为库存股份。董事会表示，对集团经营业绩、长期发展前景及H股投资价值充满信心，并认为当前股价未能充分反映公司基本面及长期增长潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675582827","title":"麦科医药-B(02335)建议采纳H股激励计划及寻求股东授出H股购回授权","url":"https://stock-news.laohu8.com/highlight/detail?id=2675582827","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675582827?lang=zh_cn&edition=full","pubTime":"2026-10-15 20:25","pubTimestamp":1792067125,"startTime":"0","endTime":"0","summary":"智通财经APP讯，麦科医药-B(02335)发布公告，于2026年10月15日(交易时段后)，董事会决议建议采纳H股激励计划，以供股东批准，并将于公司召开的临时股东会上寻求股东授出H股购回授权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1507935.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101800417","title":"麦科医药-B发布2026年9月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1101800417","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101800417?lang=zh_cn&edition=full","pubTime":"2026-10-06 16:36","pubTimestamp":1791275818,"startTime":"0","endTime":"0","summary":"陕西麦科奥特医药科技股份有限公司于2026年10月6日披露截至2026年9月30日止的证券变动月报。公告显示，本期未进行新增发行、回购、注销或库藏股相关交易，整体股本维持不变。根据公告，截至2026年9月30日，公司普通股分为H股和内资股两类。H股数量为280,071,100股，面值为每股人民币0.02元，注册股本为人民币5,601,422元；内资股数量为51,669,250股，面值为每股人民币0.02元，注册股本为人民币1,033,385元。公司本月底注册股本总额为人民币6,634,807元，与上期一致。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672796073","title":"麦科医药-B盘中涨超5% 近期获纳入股票互联互通机制股票名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2672796073","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2672796073?lang=zh_cn&edition=full","pubTime":"2026-10-02 11:09","pubTimestamp":1790910540,"startTime":"0","endTime":"0","summary":"模拟交易客户端麦科医药-B盘中涨超5%，截至发稿，股价上涨4.42%，现报21.72港元，成交额143.86万港元。麦科医药-B发布公告，根据上海证券交易所及深圳证券交易所分别于2026年9月4日及2026年9月7日发布的公告，公司的H股已获纳入股票互联互通机制的合资格股份名单，自2026年9月7日起生效。股份获纳入股票互联互通机制后，中国内地的合资格投资者可透过上海证券交易所及深圳证券交易所买卖股份。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-10-02/doc-initvazm5856798.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02335","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672796964","title":"港股异动 | 麦科医药-B(02335.HK)涨超5% 近期获纳入股票互联互通机制股票名单 MT200605的II期临床完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2672796964","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2672796964?lang=zh_cn&edition=full","pubTime":"2026-10-02 10:44","pubTimestamp":1790909044,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02335","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129671281","title":"麦科医药-B2026年中期营收0元，经调整净利润-1.12亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1129671281","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129671281?lang=zh_cn&edition=full","pubTime":"2026-09-30 17:03","pubTimestamp":1790759006,"startTime":"0","endTime":"0","summary":"本季度信息\n截至2026年6月30日止六个月，麦科医药-B（股票代码：02335）实现营收0元，与上年同期持平。经调整净利润为-1.12亿元，较上年同期-0.49亿元亏损有所扩大，主要原因包括研发投入和管理费用的上升。\n报告期内，研发费用达到1.28亿元，同比增加215.9%，系多个在研产品的临床及临床前试验费支出增幅所致；管理费用约0.33亿元，同比增加274.6%，主要由于人员扩张及股份支付等相关成本上升所致。\n经营活动现金流方面，期内实现净流入1.09亿元，而上年同期为净流出0.52亿元，转负为正主要受预收款计入现金流影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"麦科医药-B2026年中期营收0元，经调整净利润-1.12亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146317035","title":"麦科医药-B H股获纳入沪深港通合资格股份名单","url":"https://stock-news.laohu8.com/highlight/detail?id=1146317035","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146317035?lang=zh_cn&edition=full","pubTime":"2026-09-07 21:55","pubTimestamp":1788789331,"startTime":"0","endTime":"0","summary":"2026年9月7日，麦科医药-B（02335）发布自愿性公告称，公司H股已被上海证券交易所和深圳证券交易所分别于2026年9月4日及2026年9月7日公告纳入股票互联互通机制（沪港通及深港通）合资格股份名单，相关安排自2026年9月7日起生效。\n股份纳入互联互通后，中国内地的合资格投资者可通过上海证券交易所及深圳证券交易所买卖麦科医药-B的H股。\n公司在公告中指出，进入合资格名单有助于进一步扩大股东基础并提升股份的交易流动性。\n麦科医药-B董事会主席、首席执行官兼执行董事为王冰博士，公告于2026年9月7日在西安发布。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665312548","title":"麦科医药-B(02335.HK)获纳入股票互联互通机制(沪港通及深港通)股票名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2665312548","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665312548?lang=zh_cn&edition=full","pubTime":"2026-09-07 21:52","pubTimestamp":1788789133,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02335","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149812159","title":"麦科医药-B发布2026年8月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1149812159","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149812159?lang=zh_cn&edition=full","pubTime":"2026-09-02 16:58","pubTimestamp":1788339483,"startTime":"0","endTime":"0","summary":"2026年9月2日，陕西麦科奥特医药科技股份有限公司发布截至2026年8月31日的股份变动月报表。报告显示，公司已发行股份总数及注册股本在报告期内保持不变。公司披露，截至2026年8月31日，H股已发行股份为280,071,100股，内资股已发行股份为51,669,250股，两类股份数量与上月底相比均未出现增加或减少。公司表示，截至报告期末，股本数及股本结构保持稳定。本次公告由执行董事王冰签署。公司后续将继续按规定及时披露公司股份变动等相关信息。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662993500","title":"麦科医药上市首份中报亮相：经营现金流转正","url":"https://stock-news.laohu8.com/highlight/detail?id=2662993500","media":"证券日报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662993500?lang=zh_cn&edition=full","pubTime":"2026-08-28 22:01","pubTimestamp":1787925660,"startTime":"0","endTime":"0","summary":"    本报讯(记者殷高峰)8月28日，陕西麦科奥特医药科技股份有限公司(以下简称“麦科医药”)发布港交所上市后首份中期业绩。报告期内，核心管线迎来密集里程碑，经营现 ...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://baijiahao.baidu.com/s?id=1874775252433885287&wfr=spider&for=pc","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lsy1781763978866","symbols":["159399","02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662056325","title":"麦科医药－Ｂ(02335.HK)中期亏损约2.32亿元 同比增加364.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662056325","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662056325?lang=zh_cn&edition=full","pubTime":"2026-08-28 12:47","pubTimestamp":1787892424,"startTime":"0","endTime":"0","summary":"格隆汇8月28日丨麦科医药－Ｂ(02335.HK)发布截至2026年6月30日止六个月中期业绩。于报告期内，集团录得期内亏损约人民币2.32亿元，同比增加364.3%。集团的经调整亏损净额约为人民币1.12亿元，较2025年同期增加128.5%。该增加乃主要归因于研发活动的投资增加。集团录得经营活动所得现金净额约人民币1.09亿元，而2025年同期则为经营活动所用现金净额约人民币5230万元，实现了从经营现金流出净额到经营现金流入净额的转变。此乃主要归因于收到来自云顶新耀的预付款人民币2亿元。基本每股亏损0.88元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260828/32351515.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662305521","title":"麦科医药-B(02335.HK)发布中期业绩 股东应占亏损2.31亿元 同比扩大372.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662305521","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662305521?lang=zh_cn&edition=full","pubTime":"2026-08-28 12:30","pubTimestamp":1787891448,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179480337","title":"陕西麦科医药科技股份有限公司——2026年上半年亏损2.317亿元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=1179480337","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179480337?lang=zh_cn&edition=full","pubTime":"2026-08-28 12:18","pubTimestamp":1787890689,"startTime":"0","endTime":"0","summary":"陕西麦科医药科技股份有限公司（麦科医药-B）公布了截至2026年6月30日的六个月财务报告。数据显示，该公司在此期间录得亏损人民币2.317亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182025114","title":"麦科医药-B披露MT200605治疗急性缺血性脑卒中II期试验完成","url":"https://stock-news.laohu8.com/highlight/detail?id=1182025114","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182025114?lang=zh_cn&edition=full","pubTime":"2026-08-26 22:46","pubTimestamp":1787755606,"startTime":"0","endTime":"0","summary":"2026年8月26日，陝西麥科奧特醫藥科技股份有限公司公告，其自主研发的候选药物MT200605用于急性缺血性脑卒中的II期随机、双盲、安慰剂对照试验已在中国完成。该试验共入组360名受试者，并按1:1:1:1比例随机分配至10 mg BID组、20 mg BID组、40 mg BID组及安慰剂组，连续静脉输注14天。安全性数据显示，MT200605以剂量依赖方式降低AIS患者急性肾损伤发生率，高剂量组AKI发生率较安慰剂组降低80%以上。本次公告为公司自愿披露，旨在更新业务进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662742710","title":"麦科医药-B(02335)：MT200605用于急性缺血性脑卒中(AIS)的II期临床试验在中国完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2662742710","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662742710?lang=zh_cn&edition=full","pubTime":"2026-08-26 22:40","pubTimestamp":1787755220,"startTime":"0","endTime":"0","summary":"智通财经APP讯，麦科医药-B(02335)公布，集团自主研发的用于治疗急性缺血性脑卒中的候选药物MT200605的II期临床试验已完成。该临床试验已证明具有显著且稳健的疗效优势及良好的安全性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486546.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBJ","PSYK","IBBQ","BK1161","02335","MDTX","BMED","AIS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662320734","title":"麦科医药-B(02335)存仓市值总计5.21亿港元 股东将1773.41万股股票存入Merrill Lynch Far East","url":"https://stock-news.laohu8.com/highlight/detail?id=2662320734","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662320734?lang=zh_cn&edition=full","pubTime":"2026-08-25 09:07","pubTimestamp":1787620021,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，8月24日，麦科医药-B(02335)出现存仓异动，存仓市值总计5.21亿港元，占比6.33%。该公司股东将1773.41万股股票存入Merrill Lynch Far East。\r\n\r\n　　麦科医药发布公告，根据恒生指数有限公司于2026年8月21日公布的截至2026年6月30日止期间的恒生指数系列季度检讨结果，公司已获选并将纳入为恒生综合指数(恒生综指)成份股，自2026年9月7日起生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260825/32345698.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","02335"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.micot.cn","stockEarnings":[{"period":"1week","weight":-0.3992},{"period":"1month","weight":-0.341},{"period":"3month","weight":-0.5759},{"period":"6month","weight":-0.2077},{"period":"ytd","weight":-0.2077}],"compareEarnings":[{"period":"1week","weight":-0.0452},{"period":"1month","weight":-0.0701},{"period":"3month","weight":-0.0749},{"period":"6month","weight":-0.111},{"period":"1year","weight":-0.1107},{"period":"ytd","weight":-0.099}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"陕西麦科奥特医药科技股份有限公司(以下简称“麦科奥特”)于2007年1月在西安成立,现已完成西安、苏州、北京、上海、中国香港、美国布局。公司是一家专注于新药研发的创新型医药科技企业,致力于成为双功能和多功能特异性多肽药物研发的领军性前沿企业,聚焦于心脑血管、代谢性疾病、炎症疼痛相关疾病新药的研发。公司致力于创制新药、挽救生命,满足未被满足的临床需求,用科技创新为人类健康保驾护航。\n麦科奥特作为一家平台型生物技术公司,致力于加速全球新一代双特异性/多特异性多肽药物的创新及开发,我们的核心产品处于Ⅲ期临床试验。自2007年成立以来,我们专注于代谢性疾病(尤其是肾脏相关疾病)以及心脑血管疾病,作为提出双/多特异性肽技术概念的全球先驱,并凭借进入临床开发的广泛候选产品管线,我们已在该领域确立领先地位。","exchange":"SEHK","name":"麦科医药-B","nameEN":"MICOT PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"麦科医药-B(02335)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供麦科医药-B(02335)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"麦科医药-B,02335,麦科医药-B股票,麦科医药-B股票老虎,麦科医药-B股票老虎国际,麦科医药-B行情,麦科医药-B股票行情,麦科医药-B股价,麦科医药-B股市,麦科医药-B股票价格,麦科医药-B股票交易,麦科医药-B股票购买,麦科医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"麦科医药-B(02335)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供麦科医药-B(02335)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}